Congress 2014 has ended
Friday, May 2 • 2:00pm - 3:30pm
When Cancer Cells Say IDO, Indoleamine 2,3-Dioxygenase Inhibitors Say “No You Don’t”

Sign up or log in to save this to your schedule and see who's attending!

Do you know the promising potential of indoleamine (IDO) in the treatment of solid tumors and hematological malignancies? In this session, you’ll delve into the role of this immunoregulatory metabolic enzyme in immunosuppression, tumor progression, and symptom expression. You’ll review the genetic polymorphisms associated with IDO expression, the influence of IDO on tryptophan catabolism and regulatory T lymphocyte function, and clinical trials of IDO inhibitors. The effects of IDO on symptom development via tryptophan will also be explored. 

1. Describe the role of IDO in immunosuppression, tumor progression, and symptom expression.
2. Generate possible clinical applications of IDO inhibitors in cancer treatment.
3. Identify symptoms that might be experienced by patients receiving IDO inhibitors.

This session qualifies for the following ONCC Indiviudal Learning Needs Assessment (ILNA) categories.

OCN®: Scientific Basis for Practice, Treatment Modalities
AOCNP®: Cancer Treatment
AOCNS®: Cancer Treatment



Julia Eggert, PhD, GNP-BC, APRN-BC, AOCN®

Professor, Clemson University
Full disclosure: Nothing to disclose.
avatar for Lori Williams, PhD, RN, AOCN®, OCN®

Lori Williams, PhD, RN, AOCN®, OCN®

MD Anderson Cancer Center
Dr. Lori Williams is an Assistant Professor in the Department of Symptom Research at The University of Texas MD Anderson Cancer Center. Her primary focus is on hematological malignancies, with work on the symptoms of cancer and its treatment and the potential biological mechanisms... Read More →

Friday May 2, 2014 2:00pm - 3:30pm
Ballroom D Anaheim Convention Center, 800 W. Katella Avenue. Anaheim, CA 92802

Attendees (0)